X

Drug Profile

p38 MAP kinase inhibitor - Amgen

Alternative Names: AMG 548; Protein kinase 38 inhibitor - Amgen

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amgen
Class Small molecules
Mechanism of Action P38 mitogen-activated protein kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Inflammation; Rheumatoid arthritis

Most Recent Events

10 Sep 2008 Discontinued - Preclinical for Inflammation in USA (PO)
10 Sep 2008 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO)
28 Sep 2004 Preclinical trials in Inflammation in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com